Skip to main content
    K

    Kyverna Therapeutics, Inc. Common Stock (KYTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.76
    -0.29 (-5.74%)

    Market Cap: $319.27M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Kyverna Therapeutics, Inc. Common Stock (KYTX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Kyverna Therapeutics, Inc. Common Stock are Immuneering (IMRX), Keros Therapeutics (KROS) and Gyre Therapeutics (GYRE). By market cap, Kyverna Therapeutics, Inc. Common Stock ranks 10th of the 13 companies on this page; Zevra Therapeutics (ZVRA) is the largest at $540.30M.

    Peer Comparison

    KYTX's ROIC of -81.5% is below the peer median of -30.6%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Kyverna Therapeutics, Inc. Common Stock (KYTX)$319.27MN/AN/A0.0%-81.5%0.0%0.00%
    Immuneering Corp (IMRX)$240.27MN/AN/A0.0%N/A-99.8%0.00%
    Keros Therapeutics Inc (KROS)$202.13MN/A4.9x-151.4%N/A180.5%0.00%
    Gyre Therapeutics Inc. (GYRE)$471.74MN/A3.8x-22.7%N/A0.7%0.00%
    Avalo Therapeutics Inc (AVTX)$448.71MN/AN/A0.0%N/A-69.3%0.00%
    Indaptus Therapeutics Inc (INDP)$422.38MN/AN/A0.0%N/A0.0%0.00%
    Tevogen Bio Holdings Inc. (TVGN)$406.59MN/AN/A0.0%2022.8%0.0%0.00%
    Zevra Therapeutics Inc. (ZVRA)$540.30M11.6x3.7x52.8%N/A44.9%0.00%
    Neurogene Inc (NGNE)$495.37MN/AN/A0.0%-28.5%0.0%0.00%
    Candel Therapeutics Inc (CADL)$486.37MN/AN/A0.0%-43.5%0.0%0.00%
    Regenxbio Inc (RGNX)$505.18MN/A3.1x-113.9%N/A-69.2%0.00%
    CytomX Therapeutics Inc (CTMX)$444.73MN/A31.0x0.0%-32.8%-71.7%0.00%
    Inovio Pharmaceuticals Inc (INO)$267.85MN/A462.0x0.0%N/A-100.0%0.00%
    Peer median$446.72M11.6x4.4x0.0%-30.6%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Kyverna Therapeutics, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Immuneering Corp (IMRX)
    Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its...
    IMRX competitors
    Keros Therapeutics Inc (KROS)
    Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery...
    KROS competitors
    Gyre Therapeutics Inc. (GYRE)
    Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases.
    GYRE competitors
    Avalo Therapeutics Inc (AVTX)
    Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved...
    AVTX competitors
    Indaptus Therapeutics Inc (INDP)
    Indaptus Therapeutics Inc. is a pioneering biotechnology firm focused on advancing immunotherapies that aim to transform cancer treatment paradigms.
    INDP competitors
    Tevogen Bio Holdings Inc. (TVGN)
    Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology...
    TVGN competitors
    Zevra Therapeutics Inc. (ZVRA)
    Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions...
    ZVRA competitors
    Neurogene Inc (NGNE)
    Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders...
    NGNE competitors
    Candel Therapeutics Inc (CADL)
    Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform...
    CADL competitors
    Regenxbio Inc (RGNX)
    REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable...
    RGNX competitors
    CytomX Therapeutics Inc (CTMX)
    CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States.
    CTMX competitors
    Inovio Pharmaceuticals Inc (INO)
    Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development...
    INO competitors

    Frequently Asked Questions About KYTX

    Who are Kyverna Therapeutics, Inc. Common Stock's main competitors?

    The companies most similar to Kyverna Therapeutics, Inc. Common Stock include Immuneering (IMRX), Keros Therapeutics (KROS), Gyre Therapeutics (GYRE), Avalo Therapeutics (AVTX) and Indaptus Therapeutics (INDP), listed from the closest match.

    Who is Kyverna Therapeutics, Inc. Common Stock's biggest competitor?

    Zevra Therapeutics (ZVRA) is the largest of the similar companies at $540.30M; Immuneering (IMRX) is the closest match by business profile, size, sector and industry.

    How does KYTX stock compare with its competitors?

    KYTX's net margin is 0.0% against a peer median of 0.0%.

    Which of Kyverna Therapeutics, Inc. Common Stock's competitors pays a higher dividend?

    Kyverna Therapeutics, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Kyverna Therapeutics, Inc. Common Stock bigger than its competitors?

    No. Kyverna Therapeutics, Inc. Common Stock is 10th by market cap among the 13 companies on this page; the largest is Zevra Therapeutics (ZVRA) at $540.30M.